NICE recommends continuing GLP-1 therapy only if HbA1c reduces by 11 mmol/mol and weight decreases by 3% at 6 months for diabetes indications
Common side effects Nausea Diarrhea or constipation Vomiting Abdominal pain Decreased appetite Serious risks Pancreatitis (inflammation of the pancreas) Gallbladder problems Low blood sugar, especially with other diabetes medicines Kidney problems related to dehydration Serious allergic reactions Do not use if you have Personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Known serious allergy to tirzepatide Pregnancy or breastfeeding How it compares Frequently asked questions What is compounded tirzepatide
Glucagon receptor agonism promotes hepatic glucose output
Metabolism and disposition of intravenously administered acetyl-L-carnitine in healthy volunteers Eur J Clin Pharmacol 1989
Bjursell M, Admyre T, Goransson M, Marley AE, Smith DM, Oscarsson J, et al
Ask your compounding pharmacy what excipients and additives are in your specific formulation